Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.

Géza Mezey, Andrea Treszl, Andrew V. Schally, Normann L. Block, Laura Vízkeleti, Alíz Juhász, A. Klekner, János Nagy, M. Balázs, Gábor Halmos, L. Bognár

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glioblastoma (GB) is the most frequent brain tumor. Despite recent improvement in therapeutic strategies, the prognosis of GB remains poor. Growth hormone-releasing hormone (GHRH) may act as a growth factor; antagonists of GHRH have been successfully applied for experimental treatment of different types of tumors. The expression profile of GHRH receptor, its main splice variant SV1 and GHRH have not been investigated in human GB tissue samples. We examined the expression of GHRH, full-length pituitary-type GHRH receptor (pGHRHR), its functional splice variant SV1 and non-functional SV2 by RT-PCR in 23 human GB specimens. Epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog gene (PTEN) expression levels were also evaluated by quantitative RT-PCR. Correlations between clinico-pathological parameters and gene expressions were analyzed. Expression of GHRH was found to be positive in 61.9 % of samples. pGHRH receptor was not expressed in our sample set, while SV1 could be detected in 17.4 % and SV2 in 8.6 % of the GB tissues. In 65.2 and 78.3 % of samples, significant EGFR over-expression or PTEN under-representation could be detected, respectively. In 47.8 % of cases, EGFR up-regulation and PTEN down-regulation occurred together. Survival was significantly poorer in tumors lacking GHRH expression. This worse prognosis in GHRH negative group remained significant even if SV1 was also expressed. Our study shows that GHRH and SV1 genes expressed in human GB samples and their expression patterns are associated with poorer prognosis.

Original languageEnglish
Pages (from-to)1641-1649
Number of pages9
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number10
DOIs
Publication statusPublished - 2014

Fingerprint

Pituitary Hormone-Regulating Hormone Receptors
Growth Hormone-Releasing Hormone
Glioblastoma
Epidermal Growth Factor Receptor
Growth Hormone
Ligands
Genes
Gene Expression
Polymerase Chain Reaction
somatotropin releasing hormone receptor
Phosphoric Monoester Hydrolases
Brain Neoplasms
Neoplasms
Intercellular Signaling Peptides and Proteins
Up-Regulation
Down-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. / Mezey, Géza; Treszl, Andrea; Schally, Andrew V.; Block, Normann L.; Vízkeleti, Laura; Juhász, Alíz; Klekner, A.; Nagy, János; Balázs, M.; Halmos, Gábor; Bognár, L.

In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 10, 2014, p. 1641-1649.

Research output: Contribution to journalArticle

@article{e57b22aba13e400fafdb3703358530b4,
title = "Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.",
abstract = "Glioblastoma (GB) is the most frequent brain tumor. Despite recent improvement in therapeutic strategies, the prognosis of GB remains poor. Growth hormone-releasing hormone (GHRH) may act as a growth factor; antagonists of GHRH have been successfully applied for experimental treatment of different types of tumors. The expression profile of GHRH receptor, its main splice variant SV1 and GHRH have not been investigated in human GB tissue samples. We examined the expression of GHRH, full-length pituitary-type GHRH receptor (pGHRHR), its functional splice variant SV1 and non-functional SV2 by RT-PCR in 23 human GB specimens. Epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog gene (PTEN) expression levels were also evaluated by quantitative RT-PCR. Correlations between clinico-pathological parameters and gene expressions were analyzed. Expression of GHRH was found to be positive in 61.9 {\%} of samples. pGHRH receptor was not expressed in our sample set, while SV1 could be detected in 17.4 {\%} and SV2 in 8.6 {\%} of the GB tissues. In 65.2 and 78.3 {\%} of samples, significant EGFR over-expression or PTEN under-representation could be detected, respectively. In 47.8 {\%} of cases, EGFR up-regulation and PTEN down-regulation occurred together. Survival was significantly poorer in tumors lacking GHRH expression. This worse prognosis in GHRH negative group remained significant even if SV1 was also expressed. Our study shows that GHRH and SV1 genes expressed in human GB samples and their expression patterns are associated with poorer prognosis.",
author = "G{\'e}za Mezey and Andrea Treszl and Schally, {Andrew V.} and Block, {Normann L.} and Laura V{\'i}zkeleti and Al{\'i}z Juh{\'a}sz and A. Klekner and J{\'a}nos Nagy and M. Bal{\'a}zs and G{\'a}bor Halmos and L. Bogn{\'a}r",
year = "2014",
doi = "10.1007/s00432-014-1716-1",
language = "English",
volume = "140",
pages = "1641--1649",
journal = "Zeitschrift fur Krebsforschung und Klinische Onkologie",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.

AU - Mezey, Géza

AU - Treszl, Andrea

AU - Schally, Andrew V.

AU - Block, Normann L.

AU - Vízkeleti, Laura

AU - Juhász, Alíz

AU - Klekner, A.

AU - Nagy, János

AU - Balázs, M.

AU - Halmos, Gábor

AU - Bognár, L.

PY - 2014

Y1 - 2014

N2 - Glioblastoma (GB) is the most frequent brain tumor. Despite recent improvement in therapeutic strategies, the prognosis of GB remains poor. Growth hormone-releasing hormone (GHRH) may act as a growth factor; antagonists of GHRH have been successfully applied for experimental treatment of different types of tumors. The expression profile of GHRH receptor, its main splice variant SV1 and GHRH have not been investigated in human GB tissue samples. We examined the expression of GHRH, full-length pituitary-type GHRH receptor (pGHRHR), its functional splice variant SV1 and non-functional SV2 by RT-PCR in 23 human GB specimens. Epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog gene (PTEN) expression levels were also evaluated by quantitative RT-PCR. Correlations between clinico-pathological parameters and gene expressions were analyzed. Expression of GHRH was found to be positive in 61.9 % of samples. pGHRH receptor was not expressed in our sample set, while SV1 could be detected in 17.4 % and SV2 in 8.6 % of the GB tissues. In 65.2 and 78.3 % of samples, significant EGFR over-expression or PTEN under-representation could be detected, respectively. In 47.8 % of cases, EGFR up-regulation and PTEN down-regulation occurred together. Survival was significantly poorer in tumors lacking GHRH expression. This worse prognosis in GHRH negative group remained significant even if SV1 was also expressed. Our study shows that GHRH and SV1 genes expressed in human GB samples and their expression patterns are associated with poorer prognosis.

AB - Glioblastoma (GB) is the most frequent brain tumor. Despite recent improvement in therapeutic strategies, the prognosis of GB remains poor. Growth hormone-releasing hormone (GHRH) may act as a growth factor; antagonists of GHRH have been successfully applied for experimental treatment of different types of tumors. The expression profile of GHRH receptor, its main splice variant SV1 and GHRH have not been investigated in human GB tissue samples. We examined the expression of GHRH, full-length pituitary-type GHRH receptor (pGHRHR), its functional splice variant SV1 and non-functional SV2 by RT-PCR in 23 human GB specimens. Epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog gene (PTEN) expression levels were also evaluated by quantitative RT-PCR. Correlations between clinico-pathological parameters and gene expressions were analyzed. Expression of GHRH was found to be positive in 61.9 % of samples. pGHRH receptor was not expressed in our sample set, while SV1 could be detected in 17.4 % and SV2 in 8.6 % of the GB tissues. In 65.2 and 78.3 % of samples, significant EGFR over-expression or PTEN under-representation could be detected, respectively. In 47.8 % of cases, EGFR up-regulation and PTEN down-regulation occurred together. Survival was significantly poorer in tumors lacking GHRH expression. This worse prognosis in GHRH negative group remained significant even if SV1 was also expressed. Our study shows that GHRH and SV1 genes expressed in human GB samples and their expression patterns are associated with poorer prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84908239881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908239881&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1716-1

DO - 10.1007/s00432-014-1716-1

M3 - Article

C2 - 24878932

AN - SCOPUS:84908239881

VL - 140

SP - 1641

EP - 1649

JO - Zeitschrift fur Krebsforschung und Klinische Onkologie

JF - Zeitschrift fur Krebsforschung und Klinische Onkologie

SN - 0171-5216

IS - 10

ER -